INSTATAB - Trademark Details
Status: 606 - Abandoned - No Statement Of Use Filed
Serial Number
78931095
Word Mark
INSTATAB
Status
606 - Abandoned - No Statement Of Use Filed
Status Date
2011-04-25
Filing Date
2006-07-17
Mark Drawing
4000 - Standard character mark
Typeset
Published for Opposition Date
2008-01-01
Attorney Name
Law Office Assigned Location Code
M30
Employee Name
OKEKE, BENJAMIN U
Statements
Goods and Services
Pharmaceutical preparations and substances for the prevention, treatment and alleviation of stress; pharmaceutical preparations and substances for the prevention, treatment and alleviation of diabetes; pharmaceutical preparations and substances for controlling insulin levels; pharmaceutical preparations and substances for the prevention, treatment and alleviation of hypertension; pharmaceutical preparations and substances for the prevention, treatment and alleviation of angina; pharmaceutical preparations and substances for the cessation of smoking; pharmaceutical preparations and substances for the prevention and treatment of sexually transmitted diseases; pharmaceutical preparations and substances for the prevention and treatment of herpes; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the central nervous system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of depression; anti-depressants; pharmaceutical preparations and substances for the prevention, treatment and alleviation of sleep disorders; pharmaceutical preparations and substances for the prevention, treatment and alleviation of anxiety; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the cardio-vascular system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of acute myocardial infarctions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of symptomatic congestive heart failure; pharmaceutical preparations and substances for the prevention, treatment and alleviation of asymptomatic left ventricular dysfunction; pharmaceutical preparations and substances, namely, fibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the respiratory system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the endocrine system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the immune system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the musculo-skeletal system, namely, bone diseases and bone degenerative conditions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain and inflammation, namely, pain relief medication and anti-inflammatories; pharmaceutical preparations and substances for the prevention, treatment and alleviation of migraines; pharmaceutical preparations and substances, namely, medicated skin care preparations for use in dermatology, namely, dermatitis and skin pigmentation diseases; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations and substances for use in ophthalmology; pharmaceutical preparations and substances for the treatment of polycystic ovary syndrome; pharmaceutical preparations and substances for the treatment of infertility; pharmaceutical preparations and substances for the prevention, treatment and alleviation of circulatory, neurologic, alimentary, auto-immune, pulmonary, musculoskeletal, lymphatic, gastrointestinal, bone sensory, viral, urinary, renal, infectious or metabolic diseases, illnesses, disorders or conditions; metformin; diltiazem; tramadol; carvedilol; bupropion; metoprolol; citalopram; zolpidem; fluoxetine; venlafaxine; lorazepam; and sumatriptan; rapidly dissolving drug delivery agents consisting of compounds that facilitate the delivery of a wide variety of pharmaceuticals
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
6 - Active
Class Status Date
2006-07-21
Primary Code
005
Correspondences
Name
Christopher L. Graff
Address
Please log in with your Justia account to see this address.
Trademark Events
| Event Date | Event Description |
| 2006-07-21 | NEW APPLICATION ENTERED IN TRAM |
| 2006-12-13 | ASSIGNED TO EXAMINER |
| 2006-12-13 | NON-FINAL ACTION WRITTEN |
| 2006-12-13 | NON-FINAL ACTION E-MAILED |
| 2007-03-09 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| 2007-03-09 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| 2007-03-10 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| 2007-03-28 | FINAL REFUSAL WRITTEN |
| 2007-03-28 | FINAL REFUSAL E-MAILED |
| 2007-09-27 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| 2007-09-27 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| 2007-09-27 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| 2007-09-27 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| 2007-09-29 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| 2007-10-18 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| 2007-11-23 | ASSIGNED TO LIE |
| 2007-11-23 | LAW OFFICE PUBLICATION REVIEW COMPLETED |
| 2007-12-12 | NOTICE OF PUBLICATION |
| 2008-01-01 | PUBLISHED FOR OPPOSITION |
| 2008-01-14 | FAX RECEIVED |
| 2008-02-05 | ASSIGNED TO EXAMINER |
| 2008-02-05 | CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED |
| 2008-03-25 | NOA MAILED - SOU REQUIRED FROM APPLICANT |
| 2008-09-19 | TEAS EXTENSION RECEIVED |
| 2008-09-19 | EXTENSION 1 FILED |
| 2008-09-19 | EXTENSION 1 GRANTED |
| 2009-01-22 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| 2009-01-22 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| 2009-03-24 | TEAS EXTENSION RECEIVED |
| 2009-04-08 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| 2009-03-24 | EXTENSION 2 FILED |
| 2009-04-08 | EXTENSION 2 GRANTED |
| 2009-06-17 | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY |
| 2009-09-15 | TEAS EXTENSION RECEIVED |
| 2009-09-15 | EXTENSION 3 FILED |
| 2009-09-18 | EXTENSION 3 GRANTED |
| 2010-03-17 | TEAS EXTENSION RECEIVED |
| 2010-04-12 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| 2010-03-17 | EXTENSION 4 FILED |
| 2010-04-12 | EXTENSION 4 GRANTED |
| 2010-04-13 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| 2010-09-21 | TEAS EXTENSION RECEIVED |
| 2010-09-21 | EXTENSION 5 FILED |
| 2010-10-01 | EXTENSION 5 GRANTED |
| 2010-10-02 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| 2010-10-13 | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY |
| 2011-03-23 | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY |
| 2011-04-06 | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY |
| 2011-04-25 | ABANDONMENT - NO USE STATEMENT FILED |
| 2011-04-25 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED |
| 2014-01-22 | TEAS REVOKE/APPOINT ATTORNEY RECEIVED |
| 2014-01-22 | ATTORNEY REVOKED AND/OR APPOINTED |
